Clinical Trial Detail

NCT ID NCT03595124
Title A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

renal cell carcinoma

Therapies

Nivolumab

Axitinib + Nivolumab

Axitinib

Age Groups: senior adult child

No variant requirements are available.